Feedback / Questions
tavilermide (MIM-D3) - AbbVie
Allergan: Q1 FY 2016 Results
(Allergan)
-
May 13, 2016 -
Anticipated data from first P3 trial (NCT02665234) in dry eye disease in H2 2016
Anticipated P3 data
•
Dry Eye Disease • Ophthalmology
http://www.allergan.com/investors/events-presentations/events/q1-2016-allergan-plc-earnings-conference-call
May 13, 2016
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious